South San Francisco, Calif. — January 5, 2026 — Leads & Copy — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) has confirmed it will announce the results from cohort 4 of its Phase 1 clinical trial for soquelitinib in patients with moderate to severe atopic dermatitis in the second half of January 2026.
The randomized, blinded, placebo-controlled trial is evaluating soquelitinib. Due to the proximity of the data release, Corvus Pharmaceuticals is cancelling all previously planned conference attendances, including its presentation at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12th.
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as an approach to immunotherapy for immune diseases and cancer. The company’s lead product candidate, soquelitinib, is an investigational, oral, small molecule drug that selectively inhibits ITK. It is currently in a registration Phase 3 clinical trial for relapsed/refractory PTCL and a Phase 1 clinical trial for atopic dermatitis.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
Source: Corvus Pharmaceuticals
